| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 211 | 2024 | 1482 | 20.860 |
Why?
|
| Phenylbutyrates | 8 | 2024 | 72 | 2.810 |
Why?
|
| Neuroprotective Agents | 24 | 2020 | 959 | 2.610 |
Why?
|
| Clinical Trials as Topic | 36 | 2023 | 8038 | 1.950 |
Why?
|
| Superoxide Dismutase | 21 | 2018 | 593 | 1.940 |
Why?
|
| Benzothiazoles | 5 | 2016 | 245 | 1.470 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 35 | 1.420 |
Why?
|
| Motor Neurons | 20 | 2024 | 871 | 1.320 |
Why?
|
| Ceftriaxone | 5 | 2016 | 176 | 1.200 |
Why?
|
| Ubiquinone | 9 | 2019 | 181 | 1.190 |
Why?
|
| Motor Neuron Disease | 9 | 2021 | 98 | 1.180 |
Why?
|
| Double-Blind Method | 42 | 2024 | 12426 | 1.130 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2017 | 41 | 1.090 |
Why?
|
| Riluzole | 10 | 2014 | 62 | 1.070 |
Why?
|
| Muscle Strength | 9 | 2020 | 638 | 1.060 |
Why?
|
| Huntington Disease | 17 | 2020 | 1147 | 1.010 |
Why?
|
| Neurofilament Proteins | 4 | 2024 | 335 | 0.990 |
Why?
|
| Hydroxylamines | 3 | 2018 | 39 | 0.790 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 878 | 0.780 |
Why?
|
| Neurology | 5 | 2024 | 784 | 0.770 |
Why?
|
| Disease Progression | 42 | 2023 | 13616 | 0.760 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2014 | 637 | 0.750 |
Why?
|
| Vital Capacity | 9 | 2022 | 995 | 0.750 |
Why?
|
| Spinal Cord | 10 | 2021 | 1811 | 0.740 |
Why?
|
| Phenylenediamines | 1 | 2021 | 89 | 0.700 |
Why?
|
| Carbamates | 1 | 2021 | 191 | 0.650 |
Why?
|
| Nervous System Diseases | 6 | 2024 | 1657 | 0.620 |
Why?
|
| Fructose | 5 | 2010 | 285 | 0.580 |
Why?
|
| Humans | 251 | 2024 | 766117 | 0.580 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2018 | 57 | 0.570 |
Why?
|
| Drug Approval | 2 | 2022 | 820 | 0.530 |
Why?
|
| Neurosciences | 1 | 2020 | 385 | 0.490 |
Why?
|
| Middle Aged | 123 | 2024 | 223083 | 0.490 |
Why?
|
| Research Design | 14 | 2023 | 6206 | 0.470 |
Why?
|
| Evoked Potentials, Motor | 2 | 2020 | 463 | 0.440 |
Why?
|
| Treatment Outcome | 42 | 2024 | 65219 | 0.430 |
Why?
|
| Muscle, Skeletal | 12 | 2019 | 4959 | 0.430 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 5758 | 0.420 |
Why?
|
| Hand Strength | 4 | 2012 | 464 | 0.420 |
Why?
|
| Male | 137 | 2024 | 363935 | 0.420 |
Why?
|
| Patient Selection | 6 | 2016 | 4249 | 0.400 |
Why?
|
| Quadriplegia | 1 | 2014 | 227 | 0.400 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15882 | 0.400 |
Why?
|
| Female | 133 | 2024 | 396233 | 0.400 |
Why?
|
| Antioxidants | 4 | 2016 | 1671 | 0.390 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2022 | 462 | 0.390 |
Why?
|
| Nerve Growth Factors | 4 | 2022 | 564 | 0.390 |
Why?
|
| Aged | 85 | 2024 | 171219 | 0.390 |
Why?
|
| Isometric Contraction | 4 | 2017 | 149 | 0.390 |
Why?
|
| Patient Compliance | 3 | 2017 | 2694 | 0.380 |
Why?
|
| Neurodegenerative Diseases | 5 | 2024 | 1088 | 0.380 |
Why?
|
| Neural Inhibition | 1 | 2015 | 589 | 0.380 |
Why?
|
| Minocycline | 4 | 2017 | 169 | 0.370 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2022 | 1663 | 0.360 |
Why?
|
| Respiratory Insufficiency | 4 | 2021 | 1241 | 0.360 |
Why?
|
| Uric Acid | 5 | 2023 | 809 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2022 | 10737 | 0.350 |
Why?
|
| Adult | 91 | 2024 | 223139 | 0.330 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 504 | 0.330 |
Why?
|
| Information Services | 1 | 2010 | 240 | 0.320 |
Why?
|
| Mexiletine | 2 | 2020 | 30 | 0.320 |
Why?
|
| Frontotemporal Dementia | 2 | 2021 | 248 | 0.300 |
Why?
|
| Drug Delivery Systems | 3 | 2013 | 2210 | 0.290 |
Why?
|
| Lithium Chloride | 1 | 2008 | 82 | 0.290 |
Why?
|
| Pyridines | 6 | 2021 | 2889 | 0.290 |
Why?
|
| Protein C | 2 | 2019 | 134 | 0.290 |
Why?
|
| Muscles | 2 | 2011 | 1576 | 0.280 |
Why?
|
| Pentoxifylline | 2 | 2009 | 53 | 0.280 |
Why?
|
| Creatine | 4 | 2019 | 424 | 0.280 |
Why?
|
| tau Proteins | 3 | 2021 | 2110 | 0.280 |
Why?
|
| Age of Onset | 11 | 2019 | 3344 | 0.270 |
Why?
|
| Pyrazines | 3 | 2019 | 1204 | 0.270 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2018 | 213 | 0.270 |
Why?
|
| Imidazoles | 3 | 2019 | 1169 | 0.260 |
Why?
|
| Neuroglia | 3 | 2017 | 963 | 0.260 |
Why?
|
| Injections, Spinal | 5 | 2022 | 318 | 0.260 |
Why?
|
| Biomedical Research | 6 | 2024 | 3458 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 3733 | 0.260 |
Why?
|
| Nerve Degeneration | 4 | 2007 | 748 | 0.260 |
Why?
|
| Telephone | 1 | 2009 | 627 | 0.250 |
Why?
|
| Survival Analysis | 11 | 2023 | 10087 | 0.250 |
Why?
|
| Endpoint Determination | 4 | 2022 | 591 | 0.250 |
Why?
|
| Brain | 13 | 2021 | 27177 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2022 | 10380 | 0.250 |
Why?
|
| Disability Evaluation | 3 | 2010 | 1824 | 0.250 |
Why?
|
| Public Opinion | 1 | 2009 | 483 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2271 | 0.240 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2004 | 14 | 0.240 |
Why?
|
| Biological Specimen Banks | 1 | 2010 | 787 | 0.240 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2018 | 253 | 0.240 |
Why?
|
| Placebos | 4 | 2013 | 1659 | 0.230 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 185 | 0.220 |
Why?
|
| Pyramidal Tracts | 2 | 2013 | 250 | 0.220 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 778 | 0.220 |
Why?
|
| Myotonia Congenita | 1 | 2023 | 16 | 0.220 |
Why?
|
| Proteins | 2 | 2015 | 5995 | 0.220 |
Why?
|
| Lyme Disease | 1 | 2009 | 627 | 0.210 |
Why?
|
| Malignant Hyperthermia | 1 | 2023 | 72 | 0.210 |
Why?
|
| Motor Cortex | 3 | 2021 | 1004 | 0.210 |
Why?
|
| Sulfonamides | 3 | 2010 | 1980 | 0.210 |
Why?
|
| C-Reactive Protein | 4 | 2024 | 3853 | 0.210 |
Why?
|
| Vasodilator Agents | 2 | 2009 | 988 | 0.210 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 18321 | 0.200 |
Why?
|
| Erythropoietin | 1 | 2007 | 716 | 0.200 |
Why?
|
| Recovery of Function | 4 | 2022 | 2971 | 0.200 |
Why?
|
| Gene Targeting | 1 | 2006 | 840 | 0.200 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2426 | 0.200 |
Why?
|
| Pyrazoles | 3 | 2010 | 2031 | 0.200 |
Why?
|
| Physical Endurance | 2 | 2017 | 368 | 0.200 |
Why?
|
| DNA Repeat Expansion | 3 | 2021 | 74 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 1805 | 0.200 |
Why?
|
| Fragile X Syndrome | 1 | 2023 | 116 | 0.200 |
Why?
|
| Administration, Oral | 4 | 2021 | 4016 | 0.200 |
Why?
|
| Animals | 40 | 2024 | 168800 | 0.190 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2005 | 451 | 0.190 |
Why?
|
| Single-Blind Method | 5 | 2023 | 1588 | 0.190 |
Why?
|
| Glutathione Peroxidase | 1 | 2002 | 257 | 0.180 |
Why?
|
| Magnetics | 1 | 2004 | 586 | 0.180 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 418 | 0.180 |
Why?
|
| Motor Skills | 3 | 2017 | 519 | 0.180 |
Why?
|
| Internet | 2 | 2010 | 3107 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 3 | 2013 | 1729 | 0.170 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 252 | 0.170 |
Why?
|
| Deoxyguanosine | 1 | 2000 | 96 | 0.170 |
Why?
|
| Central Nervous System | 3 | 2008 | 1343 | 0.170 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 407 | 0.170 |
Why?
|
| Communication | 1 | 2014 | 3909 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 6493 | 0.170 |
Why?
|
| Patient Dropouts | 2 | 2017 | 411 | 0.160 |
Why?
|
| Meningoencephalitis | 2 | 2020 | 82 | 0.160 |
Why?
|
| Cromolyn Sodium | 1 | 2019 | 76 | 0.160 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 20137 | 0.160 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 2125 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 9237 | 0.160 |
Why?
|
| Enteral Nutrition | 3 | 2020 | 802 | 0.160 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 3722 | 0.160 |
Why?
|
| Anticonvulsants | 3 | 2021 | 1920 | 0.160 |
Why?
|
| Mitochondria | 4 | 2022 | 3672 | 0.160 |
Why?
|
| Inosine | 2 | 2023 | 129 | 0.160 |
Why?
|
| Time | 1 | 2020 | 549 | 0.160 |
Why?
|
| Lymphokines | 1 | 2001 | 905 | 0.160 |
Why?
|
| Pilot Projects | 7 | 2018 | 8724 | 0.150 |
Why?
|
| Cross-Over Studies | 2 | 2022 | 2108 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 227 | 0.150 |
Why?
|
| Respiratory Function Tests | 2 | 2020 | 1692 | 0.150 |
Why?
|
| Quinidine | 1 | 2017 | 52 | 0.140 |
Why?
|
| Cleft Palate | 1 | 2023 | 596 | 0.140 |
Why?
|
| Survival Rate | 11 | 2019 | 12827 | 0.140 |
Why?
|
| Dextromethorphan | 1 | 2017 | 37 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2010 | 3678 | 0.140 |
Why?
|
| Mice, Transgenic | 13 | 2024 | 9540 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 3690 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2009 | 200 | 0.140 |
Why?
|
| Oligonucleotides | 1 | 2020 | 561 | 0.140 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 39243 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2019 | 326 | 0.140 |
Why?
|
| Review Literature as Topic | 2 | 2009 | 297 | 0.140 |
Why?
|
| Neuralgia | 1 | 2023 | 627 | 0.140 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 14747 | 0.140 |
Why?
|
| Drug Combinations | 2 | 2020 | 2076 | 0.140 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6309 | 0.130 |
Why?
|
| Acetamides | 2 | 2017 | 260 | 0.130 |
Why?
|
| Health Status | 1 | 2010 | 4086 | 0.130 |
Why?
|
| Prognosis | 8 | 2022 | 29912 | 0.130 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2002 | 844 | 0.130 |
Why?
|
| Sulfisoxazole | 1 | 1996 | 8 | 0.130 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2017 | 116 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 437 | 0.130 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 59515 | 0.130 |
Why?
|
| Neurons | 4 | 2021 | 9521 | 0.130 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 1996 | 28 | 0.130 |
Why?
|
| MicroRNAs | 3 | 2020 | 3787 | 0.130 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 2008 | 222 | 0.130 |
Why?
|
| Research | 2 | 2017 | 1975 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 1996 | 0.130 |
Why?
|
| Nerve Regeneration | 1 | 2001 | 800 | 0.130 |
Why?
|
| Vitamins | 4 | 2019 | 1631 | 0.130 |
Why?
|
| Medical Futility | 2 | 2023 | 136 | 0.120 |
Why?
|
| Cohort Studies | 17 | 2021 | 41684 | 0.120 |
Why?
|
| Intermediate Filaments | 2 | 2020 | 171 | 0.120 |
Why?
|
| Indoles | 1 | 2023 | 1833 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 384 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2019 | 964 | 0.120 |
Why?
|
| Mice | 23 | 2024 | 81839 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 5 | 2014 | 7474 | 0.120 |
Why?
|
| Neuropsychological Tests | 3 | 2017 | 7119 | 0.120 |
Why?
|
| Immunomodulation | 2 | 2024 | 548 | 0.120 |
Why?
|
| Speech | 1 | 2020 | 555 | 0.120 |
Why?
|
| United States | 15 | 2024 | 72920 | 0.120 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 260 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2019 | 3002 | 0.110 |
Why?
|
| Young Adult | 12 | 2023 | 59868 | 0.110 |
Why?
|
| Point Mutation | 2 | 2003 | 1591 | 0.110 |
Why?
|
| Proteomics | 6 | 2012 | 3907 | 0.110 |
Why?
|
| Thrombectomy | 1 | 2019 | 676 | 0.110 |
Why?
|
| Time Factors | 12 | 2023 | 40108 | 0.110 |
Why?
|
| Formaldehyde | 1 | 2015 | 360 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 1399 | 0.110 |
Why?
|
| Electrodiagnosis | 3 | 2020 | 149 | 0.110 |
Why?
|
| Proportional Hazards Models | 9 | 2023 | 12529 | 0.110 |
Why?
|
| Databases, Factual | 7 | 2019 | 8062 | 0.110 |
Why?
|
| Home Care Services | 1 | 2020 | 659 | 0.110 |
Why?
|
| Myelin Proteins | 1 | 2014 | 212 | 0.110 |
Why?
|
| Mutation | 9 | 2020 | 30209 | 0.110 |
Why?
|
| Hospice Care | 1 | 2020 | 678 | 0.110 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2020 | 1498 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 1164 | 0.100 |
Why?
|
| PubMed | 1 | 2013 | 130 | 0.100 |
Why?
|
| Gait | 4 | 2000 | 819 | 0.100 |
Why?
|
| Axons | 1 | 2020 | 1677 | 0.100 |
Why?
|
| Propranolol | 1 | 2014 | 494 | 0.100 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2013 | 53 | 0.100 |
Why?
|
| Parkinson Disease | 5 | 2014 | 2885 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 938 | 0.100 |
Why?
|
| Reference Values | 4 | 2012 | 4909 | 0.100 |
Why?
|
| Toxicity Tests, Chronic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Depression | 2 | 2018 | 8230 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2004 | 3955 | 0.100 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2014 | 171 | 0.100 |
Why?
|
| Telemedicine | 2 | 2020 | 3108 | 0.100 |
Why?
|
| Career Choice | 1 | 2018 | 769 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 1884 | 0.100 |
Why?
|
| G-Quadruplexes | 1 | 2014 | 144 | 0.100 |
Why?
|
| Predictive Value of Tests | 10 | 2014 | 15403 | 0.100 |
Why?
|
| Thiazoles | 1 | 1999 | 1528 | 0.090 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 335 | 0.090 |
Why?
|
| Exercise Therapy | 2 | 2017 | 938 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2014 | 1638 | 0.090 |
Why?
|
| Quality of Life | 8 | 2024 | 13468 | 0.090 |
Why?
|
| Vasculitis | 1 | 1995 | 528 | 0.090 |
Why?
|
| Counseling | 1 | 2019 | 1553 | 0.090 |
Why?
|
| Neuromuscular Junction | 2 | 2019 | 399 | 0.090 |
Why?
|
| Activities of Daily Living | 3 | 2014 | 2419 | 0.090 |
Why?
|
| Apoptosis | 5 | 2012 | 9508 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 4782 | 0.090 |
Why?
|
| Body Weight | 5 | 2020 | 4626 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1437 | 0.090 |
Why?
|
| Vanadium | 1 | 2010 | 54 | 0.090 |
Why?
|
| Cocaine | 1 | 1995 | 944 | 0.090 |
Why?
|
| DNA Damage | 1 | 2000 | 2463 | 0.090 |
Why?
|
| Patient Participation | 1 | 2019 | 1447 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 452 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3140 | 0.090 |
Why?
|
| Information Management | 1 | 2010 | 100 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2023 | 81565 | 0.090 |
Why?
|
| Aging | 3 | 2007 | 8723 | 0.090 |
Why?
|
| Needles | 1 | 2013 | 460 | 0.080 |
Why?
|
| Aluminum | 1 | 2010 | 150 | 0.080 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 1413 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2018 | 1225 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3801 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2007 | 2653 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2019 | 3227 | 0.080 |
Why?
|
| Cell Count | 5 | 2007 | 1825 | 0.080 |
Why?
|
| Phenylacetates | 1 | 2009 | 112 | 0.080 |
Why?
|
| Respiratory Paralysis | 1 | 2009 | 32 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 2662 | 0.080 |
Why?
|
| Cytokines | 2 | 2021 | 7426 | 0.080 |
Why?
|
| Neuropeptide Y | 1 | 1990 | 194 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6506 | 0.080 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 897 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 1989 | 261 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 1331 | 0.080 |
Why?
|
| Dinoprost | 2 | 1999 | 139 | 0.080 |
Why?
|
| Coenzymes | 2 | 2005 | 101 | 0.080 |
Why?
|
| Galectin 3 | 1 | 2010 | 238 | 0.080 |
Why?
|
| Creatinine | 1 | 2014 | 1916 | 0.080 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 1466 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Computer Security | 1 | 2010 | 261 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 2227 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 987 | 0.080 |
Why?
|
| Gammaretrovirus | 1 | 2008 | 24 | 0.070 |
Why?
|
| Adolescent | 8 | 2023 | 88819 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2012 | 951 | 0.070 |
Why?
|
| Aryldialkylphosphatase | 1 | 2008 | 64 | 0.070 |
Why?
|
| Oxepins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Anthropometry | 1 | 2012 | 1339 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 4213 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1600 | 0.070 |
Why?
|
| Rats | 5 | 2018 | 23717 | 0.070 |
Why?
|
| Manganese | 1 | 2010 | 395 | 0.070 |
Why?
|
| Retroviridae Infections | 1 | 2008 | 148 | 0.070 |
Why?
|
| Thromboembolism | 2 | 2004 | 1001 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 3212 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 416 | 0.070 |
Why?
|
| Massachusetts | 2 | 2010 | 8882 | 0.070 |
Why?
|
| Nephrotic Syndrome | 1 | 1991 | 380 | 0.070 |
Why?
|
| Magnesium | 1 | 2010 | 815 | 0.070 |
Why?
|
| Lithium | 1 | 2010 | 599 | 0.070 |
Why?
|
| Dogs | 1 | 2012 | 3824 | 0.070 |
Why?
|
| Dyslipidemias | 2 | 2011 | 871 | 0.070 |
Why?
|
| Hair | 1 | 2010 | 509 | 0.070 |
Why?
|
| Life Tables | 2 | 2004 | 366 | 0.070 |
Why?
|
| Atrophy | 3 | 2021 | 1629 | 0.070 |
Why?
|
| Myography | 1 | 2007 | 111 | 0.070 |
Why?
|
| Thrombopoietin | 1 | 2008 | 225 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5510 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2020 | 13046 | 0.070 |
Why?
|
| Monocytes | 2 | 2014 | 2591 | 0.070 |
Why?
|
| Dyspnea | 1 | 2014 | 1351 | 0.070 |
Why?
|
| Positive-Pressure Respiration | 1 | 2011 | 712 | 0.070 |
Why?
|
| Caregivers | 2 | 2019 | 2304 | 0.070 |
Why?
|
| International Cooperation | 3 | 2018 | 1433 | 0.070 |
Why?
|
| Body Height | 1 | 2012 | 1561 | 0.070 |
Why?
|
| Electromyography | 3 | 2020 | 1398 | 0.070 |
Why?
|
| Military Personnel | 1 | 2015 | 1260 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2010 | 704 | 0.060 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2006 | 71 | 0.060 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 12803 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 790 | 0.060 |
Why?
|
| Logistic Models | 2 | 2013 | 13273 | 0.060 |
Why?
|
| Australia | 2 | 2021 | 1260 | 0.060 |
Why?
|
| Stroke | 2 | 2019 | 9748 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 3 | 2011 | 2689 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5695 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2024 | 1673 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2019 | 54812 | 0.060 |
Why?
|
| Carbon Radioisotopes | 2 | 2017 | 543 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2012 | 2244 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2702 | 0.060 |
Why?
|
| Fatty Acids | 2 | 2023 | 1805 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 1989 | 571 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2015 | 1806 | 0.060 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 213 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1949 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 1990 | 1179 | 0.060 |
Why?
|
| Hexosaminidases | 1 | 2024 | 45 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 1989 | 657 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 713 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2012 | 2646 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1407 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2009 | 5020 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2006 | 498 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2005 | 365 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 1607 | 0.060 |
Why?
|
| Data Collection | 2 | 2014 | 3318 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5367 | 0.060 |
Why?
|
| Endogenous Retroviruses | 1 | 2005 | 111 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 2901 | 0.050 |
Why?
|
| Phenotype | 7 | 2014 | 16716 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2006 | 593 | 0.050 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 2003 | 77 | 0.050 |
Why?
|
| Vitamin D | 1 | 2017 | 3272 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 746 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 297 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 552 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 895 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 1204 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2004 | 570 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2003 | 71 | 0.050 |
Why?
|
| Risk | 4 | 2016 | 9599 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2007 | 792 | 0.050 |
Why?
|
| Hybrid Cells | 1 | 2003 | 420 | 0.050 |
Why?
|
| Military Medicine | 1 | 2005 | 185 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2011 | 2114 | 0.050 |
Why?
|
| Linoleic Acids | 1 | 2022 | 39 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 993 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 150 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2007 | 1207 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2018 | 2415 | 0.050 |
Why?
|
| Genotype | 6 | 2012 | 13028 | 0.050 |
Why?
|
| Case-Control Studies | 6 | 2019 | 22228 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2024 | 211 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 731 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1656 | 0.050 |
Why?
|
| Cystatin C | 3 | 2010 | 272 | 0.050 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2023 | 226 | 0.050 |
Why?
|
| Comorbidity | 3 | 2015 | 10579 | 0.050 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 227 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2002 | 110 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 1989 | 1351 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1036 | 0.050 |
Why?
|
| Cell Death | 1 | 2007 | 1676 | 0.050 |
Why?
|
| Arm | 1 | 2004 | 590 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 1935 | 0.050 |
Why?
|
| Genome, Human | 2 | 2012 | 4443 | 0.050 |
Why?
|
| Esters | 1 | 2022 | 213 | 0.050 |
Why?
|
| Headache | 2 | 2020 | 1259 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 2 | 2000 | 145 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 164 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2006 | 614 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 12235 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2024 | 357 | 0.050 |
Why?
|
| Drug Design | 1 | 2006 | 1040 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2001 | 211 | 0.040 |
Why?
|
| Motor Activity | 2 | 2020 | 2711 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14645 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2022 | 185 | 0.040 |
Why?
|
| Survival | 2 | 2011 | 160 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2021 | 8292 | 0.040 |
Why?
|
| Reference Standards | 1 | 2004 | 1011 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2003 | 392 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 6020 | 0.040 |
Why?
|
| Vitamin E | 1 | 2005 | 872 | 0.040 |
Why?
|
| Pain | 1 | 2015 | 5090 | 0.040 |
Why?
|
| Median Nerve | 1 | 2020 | 131 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2020 | 1836 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2006 | 950 | 0.040 |
Why?
|
| Wheelchairs | 1 | 2020 | 78 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2023 | 539 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 748 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 36548 | 0.040 |
Why?
|
| Action Potentials | 4 | 2014 | 1834 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 636 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2004 | 667 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1989 | 2838 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 11906 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2001 | 472 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1084 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8347 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 442 | 0.040 |
Why?
|
| Thiazolidines | 1 | 1999 | 70 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 22341 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 671 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 1999 | 66 | 0.040 |
Why?
|
| Behavioral Symptoms | 1 | 2021 | 187 | 0.040 |
Why?
|
| Basal Ganglia | 2 | 1999 | 550 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2020 | 249 | 0.040 |
Why?
|
| Tetrabenazine | 1 | 2019 | 21 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 171 | 0.040 |
Why?
|
| Trinucleotide Repeats | 1 | 2020 | 257 | 0.040 |
Why?
|
| Periodicity | 1 | 2000 | 347 | 0.040 |
Why?
|
| Injections | 1 | 2002 | 839 | 0.040 |
Why?
|
| Safety | 1 | 2003 | 1157 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2018 | 70 | 0.040 |
Why?
|
| Sex Factors | 4 | 2020 | 10614 | 0.040 |
Why?
|
| Chorea | 1 | 1999 | 80 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2019 | 105 | 0.040 |
Why?
|
| Microglia | 3 | 2014 | 1371 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 24276 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2014 | 6324 | 0.040 |
Why?
|
| Veterans | 1 | 2012 | 2667 | 0.040 |
Why?
|
| Uncertainty | 1 | 2023 | 763 | 0.040 |
Why?
|
| Survival of Motor Neuron 2 Protein | 1 | 2017 | 49 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 292 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 1392 | 0.040 |
Why?
|
| Probability | 1 | 2023 | 2475 | 0.040 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2019 | 187 | 0.040 |
Why?
|
| Stroop Test | 1 | 2017 | 72 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2815 | 0.040 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2017 | 64 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 4556 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 590 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 4249 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 144 | 0.040 |
Why?
|
| Risperidone | 1 | 2000 | 383 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 870 | 0.040 |
Why?
|
| Marital Status | 1 | 2019 | 426 | 0.040 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2019 | 253 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2007 | 858 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 361 | 0.040 |
Why?
|
| Pandemics | 3 | 2022 | 8725 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 1999 | 376 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1321 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2009 | 103 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2018 | 539 | 0.030 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 26290 | 0.030 |
Why?
|
| Aspirin | 1 | 2008 | 3135 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 382 | 0.030 |
Why?
|
| Spirometry | 1 | 2020 | 929 | 0.030 |
Why?
|
| Italy | 1 | 2019 | 851 | 0.030 |
Why?
|
| Apathy | 1 | 2017 | 107 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2018 | 578 | 0.030 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 6545 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2014 | 18967 | 0.030 |
Why?
|
| Forecasting | 1 | 2005 | 2936 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 11035 | 0.030 |
Why?
|
| Glutathione | 1 | 1999 | 589 | 0.030 |
Why?
|
| Muscle Cramp | 1 | 2016 | 33 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 404 | 0.030 |
Why?
|
| Clozapine | 1 | 2000 | 509 | 0.030 |
Why?
|
| Cystatins | 2 | 2006 | 55 | 0.030 |
Why?
|
| Prealbumin | 2 | 2010 | 264 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 911 | 0.030 |
Why?
|
| Erythromycin | 1 | 1996 | 114 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2523 | 0.030 |
Why?
|
| Cell Survival | 2 | 2005 | 5747 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1991 | 3186 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 3249 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 1154 | 0.030 |
Why?
|
| Receptors, GABA | 1 | 2017 | 312 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2022 | 1894 | 0.030 |
Why?
|
| Child | 4 | 2023 | 80573 | 0.030 |
Why?
|
| Risk Factors | 6 | 2020 | 74857 | 0.030 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2014 | 14 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2014 | 913 | 0.030 |
Why?
|
| Dependovirus | 1 | 2020 | 721 | 0.030 |
Why?
|
| World War II | 1 | 2015 | 61 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2353 | 0.030 |
Why?
|
| Oximetry | 1 | 2018 | 461 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2016 | 295 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2005 | 2894 | 0.030 |
Why?
|
| Sheep | 1 | 1997 | 1445 | 0.030 |
Why?
|
| Acetylation | 2 | 2009 | 1054 | 0.030 |
Why?
|
| Apolipoproteins E | 2 | 2014 | 1459 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 3 | 2014 | 4399 | 0.030 |
Why?
|
| Troponin | 1 | 2018 | 532 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 4282 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2844 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 505 | 0.030 |
Why?
|
| Language | 1 | 2023 | 1550 | 0.030 |
Why?
|
| Learning | 1 | 2023 | 1755 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 435 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 1998 | 1742 | 0.030 |
Why?
|
| Lactic Acid | 1 | 1999 | 1137 | 0.030 |
Why?
|
| Research Personnel | 1 | 2018 | 589 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 355 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 1995 | 490 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2014 | 263 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 645 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 1566 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 2796 | 0.030 |
Why?
|
| Employment | 1 | 2019 | 1108 | 0.030 |
Why?
|
| Gene Expression | 1 | 2005 | 7582 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2003 | 2464 | 0.020 |
Why?
|
| Synapses | 1 | 2021 | 1759 | 0.020 |
Why?
|
| Electric Stimulation | 2 | 2007 | 1736 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2718 | 0.020 |
Why?
|
| Algorithms | 4 | 2019 | 14066 | 0.020 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2012 | 88 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 924 | 0.020 |
Why?
|
| Health Policy | 1 | 2024 | 2700 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2012 | 297 | 0.020 |
Why?
|
| Postural Balance | 1 | 2016 | 637 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 1872 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2008 | 18076 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2120 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3430 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9445 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2020 | 3400 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 3501 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 1167 | 0.020 |
Why?
|
| Peptides | 1 | 2022 | 4338 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2271 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 978 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 346 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2012 | 413 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4853 | 0.020 |
Why?
|
| Burnout, Professional | 1 | 2018 | 710 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 2003 | 8724 | 0.020 |
Why?
|
| Apyrase | 1 | 2012 | 376 | 0.020 |
Why?
|
| Terminal Care | 1 | 2001 | 1769 | 0.020 |
Why?
|
| Lanthanoid Series Elements | 1 | 2009 | 17 | 0.020 |
Why?
|
| Accidental Falls | 1 | 1997 | 1079 | 0.020 |
Why?
|
| Anterior Horn Cells | 1 | 2009 | 17 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6254 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 456 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 596 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 534 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3051 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2014 | 1518 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 3112 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2009 | 197 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1641 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6208 | 0.020 |
Why?
|
| Environmental Exposure | 2 | 2015 | 4544 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2782 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4058 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2008 | 99 | 0.020 |
Why?
|
| Cell Line | 1 | 2022 | 15546 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 798 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1225 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 2051 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1989 | 565 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 2741 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 79 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 9082 | 0.020 |
Why?
|
| Glutamine | 1 | 2010 | 575 | 0.020 |
Why?
|
| Age Factors | 2 | 2020 | 18386 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 1644 | 0.020 |
Why?
|
| Incidence | 3 | 2015 | 21513 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2762 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2008 | 643 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8525 | 0.020 |
Why?
|
| Histones | 2 | 2009 | 2591 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2014 | 11642 | 0.020 |
Why?
|
| Palliative Care | 1 | 2001 | 3639 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2022 | 14456 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2000 | 3077 | 0.020 |
Why?
|
| Neuroendocrine Secretory Protein 7B2 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 13400 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 2294 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2019 | 3712 | 0.020 |
Why?
|
| Juniperus | 1 | 2005 | 3 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2141 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 187 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 742 | 0.020 |
Why?
|
| Psychomotor Performance | 2 | 2007 | 1885 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2805 | 0.020 |
Why?
|
| Emotions | 1 | 2017 | 2758 | 0.020 |
Why?
|
| Dietary Supplements | 2 | 2011 | 3427 | 0.020 |
Why?
|
| Paresthesia | 1 | 2006 | 159 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1512 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3424 | 0.020 |
Why?
|
| Sleep | 1 | 2021 | 4816 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2009 | 430 | 0.010 |
Why?
|
| Virus Latency | 1 | 2008 | 359 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 17071 | 0.010 |
Why?
|
| Self Report | 1 | 2016 | 3769 | 0.010 |
Why?
|
| Biological Assay | 1 | 2008 | 626 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2009 | 1754 | 0.010 |
Why?
|
| Cholesterol | 1 | 2014 | 2902 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2012 | 1065 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3818 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2005 | 173 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2010 | 1181 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2000 | 3274 | 0.010 |
Why?
|
| Curcumin | 1 | 2005 | 97 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3796 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2017 | 42511 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 23605 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2014 | 4162 | 0.010 |
Why?
|
| RNA Interference | 1 | 2012 | 2828 | 0.010 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 1750 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2006 | 2161 | 0.010 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2004 | 74 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1890 | 0.010 |
Why?
|
| Death Certificates | 1 | 2004 | 172 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2007 | 515 | 0.010 |
Why?
|
| Potassium Cyanide | 1 | 2003 | 17 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2008 | 1688 | 0.010 |
Why?
|
| Cognition | 1 | 2021 | 7050 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2003 | 97 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2195 | 0.010 |
Why?
|
| Weight Loss | 1 | 2014 | 2711 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 491 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7843 | 0.010 |
Why?
|
| Free Radicals | 1 | 2003 | 237 | 0.010 |
Why?
|
| Inflammation | 1 | 2022 | 10860 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2003 | 294 | 0.010 |
Why?
|
| Spouses | 1 | 2005 | 286 | 0.010 |
Why?
|
| Cell Respiration | 1 | 2003 | 197 | 0.010 |
Why?
|
| Metabolomics | 1 | 2011 | 1667 | 0.010 |
Why?
|
| Electron Transport | 1 | 2003 | 211 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9301 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2008 | 3584 | 0.010 |
Why?
|
| Hippocampus | 1 | 2014 | 3773 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2012 | 4025 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12061 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 5128 | 0.010 |
Why?
|
| Quality Control | 1 | 2004 | 835 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2004 | 1263 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2006 | 1186 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1984 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2005 | 657 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2005 | 1133 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2008 | 3623 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2007 | 1756 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 16040 | 0.010 |
Why?
|
| Face | 1 | 2006 | 1029 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 3270 | 0.010 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2000 | 108 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 713 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8924 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4112 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 1325 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 4617 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 1671 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 410 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 2270 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2915 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4133 | 0.010 |
Why?
|
| Viral Load | 1 | 2008 | 3386 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1407 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 934 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 1167 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 2611 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 1867 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 2727 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12976 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2003 | 908 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2005 | 2495 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10433 | 0.010 |
Why?
|
| Sample Size | 1 | 2000 | 843 | 0.010 |
Why?
|
| Locomotion | 1 | 1998 | 384 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 36427 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 6059 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 3432 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15827 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6102 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 2144 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 3594 | 0.010 |
Why?
|
| Family | 1 | 2005 | 3208 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5784 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 12130 | 0.010 |
Why?
|
| Life Style | 1 | 2004 | 3928 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 20700 | 0.010 |
Why?
|
| Educational Status | 1 | 2000 | 2510 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 6892 | 0.010 |
Why?
|
| Reaction Time | 1 | 1998 | 2086 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 5791 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 5926 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 9527 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12775 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 5873 | 0.000 |
Why?
|